Halozyme Therapeutics (LTS:0J2O) 3-Year Book Growth Rate : -16.10% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Halozyme Therapeutics 3-Year Book Growth Rate?

Halozyme Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $1.40.

During the past 12 months, Halozyme Therapeutics's average Book Value per Share Growth Rate was 179.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was -16.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was -7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Halozyme Therapeutics was 234.20% per year. The lowest was -39.30% per year. And the median was -5.90% per year.

Competitive Comparison of Halozyme Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Halozyme Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's 3-Year Book Growth Rate falls into.

Halozyme Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Halozyme Therapeutics (LTS:0J2O) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Halozyme Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (LTS:0J2O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (LTS:0J2O) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

HALO:USA RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (LTS:0J2O) Headlines

No Headlines